08:15 AM EDT, 08/26/2025 (MT Newswires) -- Allarity Therapeutics ( ALLR ) said Tuesday that the US Food and Drug Administration has granted fast-track designation to stenoparib, the company's investigational treatment for patients with advanced ovarian cancer.
Shares of the company rose more than 36% in recent Tuesday premarket activity.
The fast track designation enables expedited development and review of drugs that are intended to treat serious conditions and fill an unmet medical need, the company said.
Price: 1.24, Change: +0.32, Percent Change: +33.86